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increased use of prophylaxis. Few studies have analyzed
the total costs of treatment, hence we undertook this
study. METHODS: To determine total costs and trends
of treating children with severe hemophilia-A from 1978
to 1998, at the Hospital for Sick Children in Toronto, one
patient chart reviewer identiﬁed resource consumption of
all patients (n = 17). For each patient, costs for factor con-
centrate, clinic visits, physicians and healthcare profes-
sionals (physiotherapists/social workers), laboratory and
other tests (x-ray, MRI, ultrasound) and hospitalizations
were determined. Costs in Canadian dollars were taken
from standard lists and discounted at 3%. RESULTS:
Total average cost (range) was $69,322 ($14,471–
$108,294)/year/patient of which the largest part, $65,184
($8,250–$107,104), 94% (57%–99%) was accounted for
by Factor-VIII. Hospitalizations accounted for $2,396
($0–$57,063)/patient/year including drugs, nursing care
and stay. Clinic visits and physician visits were $1290
($122–$4143) and $177 ($0–$308), respectively. Health-
care professionals averaged $89 ($0–$252) and lab tests
and other tests cost $156 ($26–$226) and $31 ($4–
$70)/patient/year, respectively. The average number of
bleeds was 12.9 (2.0–22.0)/patient/year. Since 1978, the
average number of bleeds decreased by 0.71 (r2 = 0.56)/
patient/year. The average number of hospitalizations 
was 0.21 (0–4)/patient/year, in which patients stayed on
average 10.7 (1–135) days. Since 1984, the number of
hospitalizations has decreased by 0.5 hospitalizations/
patient/year (r2 = 0.74). Concurrently, the average costs
of the treatment of severe hemophiliacs have increased by
approximately $3740 (r2 = 0.62)/patient/year. Clotting
factor concentrate cost per patient increased by $4215 (r2
= 0.66)/year, of which prophylaxis accounted for $1429
(r2 = 0.60)/year, while on demand Factor-VIII costs
decreased by $497 (r2 = 0.16)/year. CONCLUSIONS:
The annual cost of hemophilia care, of $69,322 per
patient, is substantial. The number of bleeds and 
hospitalizations is decreasing while there was a clear
trend in increasing costs of treating severe hemophiliacs,
primarily associated with increasing use of prophylactic
treatment.
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OBJECTIVES: In Asia, individuals with hemophilia are
often treated with cryoprecipitate as it is considered a less
expensive option. However, the risk of acquiring blood-
borne infections is higher with cryoprecipitate than with
factor concentrates. Any acquisition cost savings that
occur with the use of cryoprecipitate may be offset by
greater total healthcare costs to treat transmissible
viruses. METHODS: A literature review was conducted
to obtain estimates of the prevalence of HIV, HBV and
HCV in the blood supply and costs of treating the sub-
sequent diseases. Data from international health organi-
zations, local experts in the treatment of hemophilia, and
the local Red Cross Society was utilized. This data forms
the basis of an economic and outcomes model for hemo-
philia treatment in this Asian country. RESULTS: Based
on the data identiﬁed, the risk of exposure to the blood-
borne infections in hemophiliacs treated with cryoprecip-
itate is substantial: 3%, 6% and 12% at 5, 10 and 20
years respectively for HIV. Risk for developing hepatitis
infection was higher. The discounted cost of treating 
the three infectious diseases is substantial. For patients
treated with cryoprecipitate total treatment costs were
$26,575 and $64,291.06 at 10 and 20 years. For patients
treated with factor concentrate equivalent costs were
$32,200 and $64,401. CONCLUSIONS: Over time, the
acquisition cost savings associated with cryoprecipitate
use, compared to factor concentrate, disappears as the
costs for treating transmissible viruses in infected patients
increases.
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OBJECTIVES: To investigate whether long-term growth
hormone (GH) replacement therapy in GH deﬁcient
(GHD) adults results in improvements in Quality of Life
(QoL), patient-reported outcomes and health care uti-
lization (HCU) in the Netherlands. METHODS: The
analysis was based on 74 patients (35 men, 39 women)
and all patients were included in KIMS (Pharmacia Inter-
national Metabolic Survey)—the largest pharmacoepi-
demiological survey of GHD adults on GH therapy. Data
were available for all patients for the ﬁrst year of treat-
ment, and 2-year follow-up data were available for 38
patients. QoL was assessed using the Nottingham Health
Proﬁle (NHP) and disease-speciﬁc AGHDA question-
naire. Patient reported outcomes and data on HCU were
obtained with the Patient Life Situation Form (PLSF). Sta-
tistical analyses were performed with repeated measure-
ments technique. RESULTS: Both QoL questionnaires
showed a signiﬁcant improvement after 1 and 2 years of
GH therapy (from 20.1 ± 2.6 to 10.1 ± 2.5 for NHP, from
9.3 ± 0.82 to 7.2 ± 1.11 for AGHDA). Data collected
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with the PLSF showed a subjective improvement in 
personal well-being for 65% of the patients after 1 and
2 years of GH treatment. Visits to the doctor in the pre-
vious year (from 9.1 ± 1.4 to 3.4 ± 1), days in hospital
(from 7.9 ± 2.6 to 1.6 ± 1.5) and days of sick leave (from
26.4 ± 9.8 to 2.2 ± 1.1) signiﬁcantly decreased during 
GH therapy. Leisure-time physical activity signiﬁcantly
improved during therapy, whereas satisfaction with phy-
sical activity improved only in females. Another gender
difference relates to the need for assistance with daily
activities, which remained low and constant in males, 
but seemed to worsen in females. CONCLUSION: Data
obtained so far conﬁrm that GH replacement therapy
results in a signiﬁcant long-term improvement of both
QoL and general well being and reduction of HCU in 
the Netherlands. Moreover, after two years of GH
therapy both QoL and HCU levels become comparable
to the general Dutch population.
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OBJECTIVES: We report the development of an instru-
ment to assess feelings about self-injection of growth
hormone (GH) in adolescents with growth disorders.
METHODS: Adolescents (age 11–19 years) in 2 cohorts
(UK N = 74 and USA N = 98) completed a 10-item GH
questionnaire, as well as health-related quality of life
(HRQOL), functional status scales, self-control, and self-
esteem scales to assess external validity. The GH and
HRQOL questionnaires were repeated in 2–4 weeks.
RESULTS: The GH questionnaire contains 10 items in 2
subscales (feelings, injection issues) and a total summary
score, with higher scores indicating better acceptance 
of GH. Internal consistency reliabilities were a = 0.77
Summary Score, a = 0.68 Feelings, and a = 0.78 Injection
Issues, with overall test-retest reliability 0.72, and no
ﬂoor or ceiling effects. Signiﬁcant summary score corre-
lations with external validity scales were 0.42 HRQOL,
0.34 functional status, 0.25 self-control. Mean summary
scores did not differ signiﬁcantly by cohort, age, gender,
or diagnosis (range 4.0–4.4 points). The Injection Issues
component was signiﬁcantly associated with all VSP-AM
subscales and total score (all p < 0.01), whereas the Feel-
ings component was signiﬁcantly correlated with self-
esteem, well-being, physical health and the total score (all
p < 0.01) as well as with teachers (p < 0.05). CONCLU-
SIONS: The GH Injection Questionnaire is both a reli-
able and valid measure of attitudes for adolescents with
growth disorders. It measures different constructs than
other instruments. Adolescents who were more comfort-
able with GH injections had higher HRQOL, functional
capacity, and self-control.
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OBJECTIVES: The beneﬁcial effects of growth hormone
(GH) replacement in patients with GH deﬁciency (GHD)
are now well recognized. Moreover, ﬁrst evidence that
these effects are accompanied by a reduction in the use
of healthcare resources has been provided by KIMS, the
Pharmacia International Metabolic Database of adult
GHD patients receiving GH therapy (Genotropin, 
Pharmacia Corp.). The aim of the present study was to
investigate effects of GH replacement in the German
KIMS cohort. METHODS: The analysis was based on
105 patients (65m, 40w) with GHD. 1-year follow-up
was available from all patients, 2-year follow-up from 
60 patients. Statistical analyses were performed with
repeated measurements technique. RESULTS: QoL, mea-
sured by Nottingham Health Proﬁle (NHP) and QoL-
Assessment in GHD Adults (QoL-AGHDA) signiﬁcantly
improved after 1 and 2yrs of GH therapy (NHP distress
index: 5.4 ± 4.4 (mean ± SD), 1yr 3.7 ± 4.2 (p < 0.001),
2yrs 4.1 ± 5.0; QoL-AGHDA score: 9.4 ± 6.3, 1yr 6.4 ±
6.1 (p < 0.001), 2yrs 6.3 ± 6.4 (p < 0.001)). Patient-
reported outcomes were collected with help of Patient
Life Situation Form. 64.0% reported subjective improve-
ment at 1yr, and 78.9% at 2yrs (2nd vs. 1st yr: p < 0.05).
Visits to the doctor per yr (8.2 ± 6.9, 1yr 4.8 ± 7.2 (p <
0.001), 2yrs 3.9 ± 5.0 (p < 0.001)), days in hospital (14.6
± 20.5, 1yr 0.9 ± 3.3 (p < 0.001), 2yrs 0.4 ± 1.8 (p <
0.01)), and days of sick leave (23.8 ± 33.3, 1yr 1.7 ± 3.5
(p < 0.05), 2yrs 3.0 ± 4.2 (p < 0.05)) signiﬁcantly
decreased during GH therapy. Males presented a signiﬁ-
cantly better QoL score in terms of NHP distress index
(p < 0.02). Need for assistance with daily activities
decreased only in females from 30.8% to 19.1%. CON-
CLUSIONS: This country speciﬁc analysis of the German
KIMS cohort conﬁrms signiﬁcant reduction in the use of
healthcare resources as well as signiﬁcant improvements
in QoL and patient reported outcomes during GH
replacement in previously untreated adults with GHD.
Improvements in QoL seem to be more pronounced in
males, whereas females showed a higher reduction of the
need for assistance in daily activities.
